Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Firebrick Pharma Limited ( (AU:FRE) ) is now available.
Firebrick Pharma Limited will present at the NWR Virtual Healthcare Conference, with Executive Chair Dr Peter Molloy scheduled to speak in a live online session on 26 March 2026, followed by a recorded replay available via the conference link, company website, and social media channels. The event offers shareholders and investors an opportunity to hear directly from management as Firebrick advances the international roll-out of its Nasodine povidone-iodine product range and pursues broader market approvals, reinforcing its positioning in the over-the-counter respiratory health segment.
Firebrick Pharma Limited is an Australian pharmaceutical company focused on developing and commercialising novel formulations and uses of povidone-iodine. Its lead product, Nasodine Nasal Spray, has been introduced in the United States, Singapore, and Fiji & the South Pacific, with regulatory expansion targeted to additional markets such as the Philippines.
The company is also rolling out Nasodine Throat Spray in Singapore and Fiji and plans to build a four-product Nasodine range across up to 10 markets over the next three years. Firebrick’s participation in the NWR Virtual Healthcare Conference provides additional visibility among healthcare-focused investors as it executes its global growth strategy.
The most recent analyst rating on (AU:FRE) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Firebrick Pharma Limited stock, see the AU:FRE Stock Forecast page.
More about Firebrick Pharma Limited
Firebrick Pharma Limited is an Australian pharmaceutical company focused on developing and commercialising novel formulations and uses of povidone-iodine. Its lead product, Nasodine Nasal Spray, has been introduced in the United States, Singapore, and Fiji & the South Pacific, with regulatory expansion targeted to additional markets such as the Philippines. The company is also rolling out Nasodine Throat Spray in Singapore and Fiji and plans to build a four-product Nasodine range across up to 10 markets over the next three years.
Average Trading Volume: 66,514
Technical Sentiment Signal: Sell
Current Market Cap: A$14.64M
Learn more about FRE stock on TipRanks’ Stock Analysis page.